BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 55
- Registration Number
- NCT00371254
- Locations
- 🇺🇸
Dana-Farber Cancer Inst, Boston, Massachusetts, United States
🇺🇸University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States
🇪🇸Local Institution, Lleida, Spain
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
- Conditions
- Deep Vein ThrombosisPulmonary Embolism
- Interventions
- First Posted Date
- 2006-09-04
- Last Posted Date
- 2015-12-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3608
- Registration Number
- NCT00371683
- Locations
- 🇺🇸
Martin Bowen Hefley Orthopedics, Little Rock, Arkansas, United States
🇺🇸Jewett Orthopaedic Clinic, Winter Park, Florida, United States
🇺🇸Atlanta Knee And Sports Medicine, Decatur, Georgia, United States
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
- First Posted Date
- 2006-09-01
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 131
- Registration Number
- NCT00371150
- Locations
- 🇺🇸
Alabama Liver & Digestive Specialists (Alds), Montgomery, Alabama, United States
🇺🇸University Of Arizona, Tucson, Arizona, United States
🇺🇸Empire International Research, Miami, Florida, United States
Drug Interaction Study With Famotidine, Atazanavir, and Atazanavir/Ritonavir/Tenofovir
- Conditions
- HIV Infections
- Interventions
- Drug: Atazanavir+Ritonavir+TenofovirDrug: Atazanavir+Ritonavir+Tenofovir+Famotidine
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00365339
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT00364793
- Locations
- 🇹🇭
Local Institution, Bangkok, Thailand
A Study of the Alternative Administration of Ixabepilone and Vinflunine
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT00362830
- Locations
- 🇺🇸
University Of Miami Miller School Of Medicine, Miami, Florida, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14
- Registration Number
- NCT00362726
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2009-11-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3
- Registration Number
- NCT00362466
- Locations
- 🇺🇸
Santee Hematology/Oncology, Sumter, South Carolina, United States
🇺🇸M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States
🇺🇸Local Institution, Houston, Texas, United States
Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT00362713
- Locations
- 🇺🇸
The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Vinflunine in Patients With Gastric Cancer
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 55
- Registration Number
- NCT00359476
- Locations
- 🇵🇭
Local Institution, Quezon City, Philippines